Cervical Intraepithelial Neoplasia Clinical Trial
Official title:
A Comparison Study of Two Community Outreach-Based Approaches to Increase Participation of Women Living in the Mississippi Delta in Cervical Cancer Screening
Verified date | April 13, 2011 |
Source | National Institutes of Health Clinical Center (CC) |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
Background:
- The Mississippi Delta (which includes the counties along the Mississippi River) is one
of the poorest areas in the United States. Women living in the Mississippi Delta have
disproportionately high rates of cervical cancer, but they are unlikely to come to
clinics except perhaps for giving birth, years before they are diagnosed with cancer.
- To improve rates of screening, researchers are attempting an outreach study to see
whether under-screened women, if approached by door-to-door recruitment, would get
screened by one of two methods (home-based self-collection and testing, or a clinic
exam) and which method they would prefer.
Objectives:
- To assess/measure increased participation of under-screened women living in the Mississippi
Delta in cervical cancer screening by offering women the opportunity to get screened by one
of two possible community outreach-based cervical cancer screening modalities,
self-collection and HPV testing or clinic-based cytology screening, the current standard of
care.
Eligibility:
- Women between 26 and 65 years of age, who are not pregnant currently or in the past 8
weeks, have an intact cervix, have no history of cancer, and have not been screened for
cervical cancer in the past 3 years.
Design:
- Researchers will recruit participants on a door-to-door basis. Researchers will recruit
all eligible women within a household. Recruitment will be done only during daylight
hours but at the end of the working day to maximize the chances of finding women at
home.
- Eligible women willing to participate will complete a questionnaire with demographic and
medical information.
- Participants will be asked to choose the screening method of their preference. If they
choose self-collection with HPV testing, they will be given a self-collection kit and
asked to perform the self-collection and return the kit within 1 month. Participants who
choose to have cytology screening will be provided with the phone number and location of
the local health department clinic and will be encouraged to schedule their screening
within the following month.
- Women who do not complete their participation within 1 month will be considered
noncompliant with their chosen intervention. Researchers will re-contact noncompliant
women to offer them participation in the study, including permitting them to refuse to
participate or to choose the alternative intervention....
Status | Completed |
Enrollment | 400 |
Est. completion date | April 13, 2011 |
Est. primary completion date | |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 26 Years to 65 Years |
Eligibility |
- INCLUSION CRITERIA: - Women who are age 26-65 years, not pregnant currently or in the past 8 weeks, who have an intact cervix, no history of cancer, have not been screened for cervical cancer in the last 3 years, and able and competent to provide informed consent will be considered eligible for the study. EXCLUSION CRITERIA: - Women under 26 or over 65 years of age. - Pregnant women or women who have given birth to a child in the past 8 weeks. To insure women included in the study are not pregnant, we will ask women during the consenting process if they are pregnant or gave recently given birth. Women who answer yes for either query will be excluded. - Women who have had a total hysterectomy. - History of cervical cancer - Screened for cervical cancer in the last 3 years. - Other reasons to exclude women include the inability to speak English, the appearance of mental incompetence, or refusal to participate or sign the informed consent form. |
Country | Name | City | State |
---|---|---|---|
United States | National Cancer Institute (NCI), 9000 Rockville Pike | Bethesda | Maryland |
Lead Sponsor | Collaborator |
---|---|
National Cancer Institute (NCI) |
United States,
Cuzick J, Clavel C, Petry KU, Meijer CJ, Hoyer H, Ratnam S, Szarewski A, Birembaut P, Kulasingam S, Sasieni P, Iftner T. Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int J Cancer. 2006 Sep 1;119(5):1095-101. — View Citation
Dillner J, Rebolj M, Birembaut P, Petry KU, Szarewski A, Munk C, de Sanjose S, Naucler P, Lloveras B, Kjaer S, Cuzick J, van Ballegooijen M, Clavel C, Iftner T; Joint European Cohort Study. Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study. BMJ. 2008 Oct 13;337:a1754. doi: 10.1136/bmj.a1754. — View Citation
Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ. Cancer statistics, 2008. CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96. doi: 10.3322/CA.2007.0010. Epub 2008 Feb 20. — View Citation
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT04537156 -
Efficacy, Immunogenicity and Safty Study of Recombinant Human Papillomavirus Vaccine(6,11,16,18,31,33,45,52,58 Type)(E.Coli)
|
Phase 3 | |
Completed |
NCT02907333 -
Testing Use of Condoms on Regression of Cervical Intraepithelial Neoplasia
|
N/A | |
Recruiting |
NCT02576262 -
HPV Integration Testing for Human Papillomavirus-Positive Women
|
N/A | |
Completed |
NCT01029990 -
Randomized Controlled Trial to Study Interventions to Increase Participation in Cervical Cancer Screening Program
|
Phase 0 | |
Recruiting |
NCT05078528 -
Low-cost Imaging Technology for Global Prevention of Cervical Cancer
|
N/A | |
Recruiting |
NCT05502367 -
A Study of ABI-2280 Vaginal Tablet in Participants With Cervical Intraepithelial Neoplasia
|
Phase 1/Phase 2 | |
Completed |
NCT02494310 -
HRME: Screening for Cervical Cancer and Its Precursors in Low‐Resource Settings
|
N/A | |
Active, not recruiting |
NCT03429582 -
Comparison of Cervical CIN II/III Treatment Outcomes With Thermal Ablation Device
|
N/A | |
Active, not recruiting |
NCT02140021 -
Biospecimen Collection and Testing for the Prevalence of Anal Dysplasia and Anal Cancer in Patients With Cervical, Vaginal and Vulvar Dysplasia and Cancer
|
N/A | |
Not yet recruiting |
NCT05510830 -
Diagnostic Cervical Conization for Persistent Infection or Integration of HPV
|
N/A | |
Completed |
NCT02237326 -
Visual Inspection With Acetic Acid Compared to Lugol's Iodine in HIV-infected Women
|
N/A | |
Completed |
NCT00316706 -
Human Papilloma Virus (HPV) Vaccine Trial in Young Adolescent Women With GlaxoSmithKline Biologicals' (GSK Bio) HPV-16/18 Vaccine
|
Phase 3 | |
Withdrawn |
NCT03143491 -
Study of SOR007 Ointment for Cervical Intraepithelial Neoplasia (CIN)
|
Phase 2 | |
Completed |
NCT03293628 -
Comparing Two Techniques of Haemostasis After Cervical Conization
|
Phase 2 | |
Recruiting |
NCT05266898 -
Immunogenicity of Gardasil-9 HPV Vaccine in People Living With HIV
|
Phase 4 | |
Completed |
NCT02481414 -
A Clinical Trial of PepCan to Two Therapy Arms for Treating Cervical High-Grade Squamous Intraepithelial Lesions
|
Phase 2 | |
Completed |
NCT02247999 -
Improving Cervical Cancer Screening Among HIV-Infected Women in India
|
||
Recruiting |
NCT04650711 -
Immunohistochemical Staining of p16 for the Screening of Cervical Cancer
|
Phase 2 | |
Recruiting |
NCT04646954 -
DNA Methylation Testing for the Screening of Uterine Cervical Lesion
|
Phase 3 | |
Completed |
NCT01544478 -
V501 Safety and Efficacy Study in Japanese Women Aged 16 to 26 Years (V501-110)
|
Phase 4 |